FALCON trial of fulvestran for advanced breast cancer: subgroup analysis and overall survival

FALCON trial of fulvestran for advanced breast cancer: subgroup analysis and overall survival

VJOncology

3 years
332 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Matthew Ellis, MB, BChir, PhD, FRCP of Baylor College of Medicine, Houston, TX discusses take-home messages from the Phase III FALCON randomized trial of fulvestran versus anastrozole for hormone receptor-positive advanced breast cancer (NCT01602380). Prof. Ellis explains that one of the take-home messages comes from a subgroup analysis. Patients with hormone receptor-positive advanced breast cancer form a very heterogenous group; a typical patient on the FALCON trial had non-visceral disease. In this group, the advantage for fulvestran seems more dramatic as Prof. Ellis explains. Further, the overall survival (OS) data for using fulvestran upfront is not known yet; there is a hypothesis from an earlier, smaller, open-label study suggesting that fulvestran could be associated with an OS advantage if used frontline but the study was not big enough to be definitive. According to Prof. Ellis, we will know about OS in around 18 months to two years when the study is fully matured. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
Up Next Autoplay
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
2 Views
UVA Cancer Center 3 hours
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Category: News
3 Views
alexvarney 8 hours
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Category: Brain Cancer
2 Views
alexvarney 9 hours
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Kidney Cancer
36 Views
kidneycancer 1 day
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
11 Views
UVA Cancer Center 1 day
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
3 Views
Cancer-News 1 day
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
12 Views
kidneycancer 2 days
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
9 Views
kidneycancer 2 days
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
4 Views
CURC 2 days
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 2 days